The publisher's Medical Devices sector report, “Diabetes Assays - Medical Devices Pipeline Product Landscape, 2021' provides comprehensive information about the Diabetes Assays pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Diabetes Assays are intended for the quantitative determination of biomolecules, such as glycated haemoglobin, c-peptide, insulin etc to diagnose diabetes related disorders.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Diabetes Assays are intended for the quantitative determination of biomolecules, such as glycated haemoglobin, c-peptide, insulin etc to diagnose diabetes related disorders.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Diabetes Assays under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Diabetes Assays and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to -- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Diabetes Assays under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Diabetes Assays - Pipeline Products under Development by Companies
5 Diabetes Assays Companies and Product Overview
7 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abcodia Ltd
- Adaptive Biotechnologies Corp
- Adipomics Inc
- ADiTx Therapeutics Inc
- Alfa Wassermann Inc
- AmideBio LLC
- Aura Biotechnologies Pvt Ltd
- Beckman Coulter Inc
- Biocrates Life Sciences AG
- BioDesign Institute at Arizona State University
- CellCarta Precision Medicine Inc
- Confer Health Inc
- Drexel University
- ELITechGroup Inc
- Enable Biosciences Inc
- FibroStatin SL
- Gelteq Pty Ltd
- Genesis Detection Systems, Inc.
- Helmholtz Centre for Infection Research
- Hemex Health Inc
- Human Cell Design SAS
- IntraMed Diagnostics, LLC
- Janssen Diagnostics LLC
- Johns Hopkins University
- L2 Diagnostics LLC
- Mellitus LLC
- Numares AG
- Peri Rx Inc
- PortaScience Inc
- Precision Diabetes LLC
- Protagen AG
- Queen Mary University of London
- QuickCheck Health Inc
- Sebia SA
- Sera Prognostics Inc
- Singulex Inc
- SomaLogic Inc
- The Forsyth Institute
- University of Canterbury
- University of Colorado
- University of Florida
- University of Newcastle
- University of Oxford
- University of South Florida
- University of Strathclyde
- Xhale Inc
- Yaathum Biotech Pvt Ltd
